








CD Markers

Antibodies Targeting CD Markers





bioxcell.com





CD Marker Antibodies



Antigen	Reactivity	Application	Clone	<i>InVivoMab</i> Catalog	<i>InVivoPlus</i> Catalog
CD1a	human	<i>in vitro</i> CD1a blockade, FC	OKT-6	BE0211	BE0083
CD1d (CD1.1)	mouse	<i>in vivo</i> CD1d neutralization	19G11	BE0000	BE0088
CD1d (CD1.1)	mouse	iNKT cell neutralization, <i>in vivo</i> CD1d blockade, FC	20H2 (HB323)	BE0179	BE0088
CD3	human	<i>in vitro</i> T cell stimulation/activation, <i>in vivo</i> T cell depletion in humanized mice, ex vivo T cell inhibition for xenographs, FC	OKT-3	BE0001-2	BE0085
CD3	mouse	<i>in vitro</i> T cell stimulation/activation	17A2	BE0002	BE0090
CD3	human	<i>in vivo</i> T cell depletion in humanized mice, ex vivo T cell inhibition for xenographs, FC	UCHT1 (Leu-4) (T3)	BE0231	BE0083
CD3ε	mouse	<i>in vivo</i> T cell depletion, <i>in vitro</i> T cell stimulation/activation, IF, FC	145-2C11	BP0001-1	BP0091
CD3ε	mouse	<i>in vitro</i> T cell negative selection, <i>in vitro</i> T cell stimulation/activation, IF	KT3	BE0261	BE0089
CD3ε F(ab') ₂ fragment	mouse	<i>in vivo</i> T cell depletion	145-2C11 F(ab') ₂ Fragments	BE0001-1FAB	BE0091-FAB
CD4	mouse	<i>in vivo</i> CD4 ⁺ T cell depletion, FC	GK1.5	BP0003-1	BP0090
CD4	human	<i>in vitro</i> T cell stimulation/activation, <i>in vivo</i> CD4 ⁺ T cell depletion in humanized mice, FC, IP	OKT-4	BE0003-2	BE0086
CD4	mouse	<i>in vivo</i> blockade of CD4 ⁺ T-cell responses, WB	YTS 177	BE0003-3	BE0089
CD4	mouse	<i>in vivo</i> CD4 ⁺ T cell depletion	YTS 191	BE0119	BE0090
CD4	human	<i>in vitro</i> CD4 blockade, <i>in vitro</i> blocking of CD4 ⁺ T cell activation, IF, IHC-F, FC	RPA-T4	BE0288	BE0083
CD4	rat	<i>in vivo</i> CD4 ⁺ T cell depletion, FC	OX-38	BE0308	BE0085
CD8 (Lyt 2.1)	mouse	<i>in vivo</i> CD8 ⁺ T cell depletion, FC	116-13.1 (HB129)	BE0118	BE0085
CD8α	mouse	<i>in vivo</i> CD8 ⁺ T cell depletion, IF, FC	53-6.7	BP0004-1	BP0089
CD8α	human	<i>in vivo</i> CD8 ⁺ T cell depletion in humanized mice	OKT-8	BE0004-2	BE0085
CD8α	mouse	<i>in vivo</i> CD8 ⁺ T cell depletion	2.43	BP0061	BP0090
CD8α	mouse	<i>in vivo</i> CD8 ⁺ T cell depletion	YTS169.4	BP0117	BP0090
CD8β (Lyt 3.2)	mouse	<i>in vivo</i> CD8 ⁺ T cell depletion, <i>in vitro</i> CD8 blockade, IF	53-5.8	BE0223	BE0088
CD11a (LFA-1α)	human	<i>in vitro</i> LFA-1 neutralization	TS-1/22.1.13	BE0005	BE0083
CD11a (LFA-1α)	mouse	<i>in vivo</i> LFA-1 neutralization	FD441.8	BE0005-1	BE0090
CD11a (LFA-1α)	mouse	<i>in vivo</i> LFA-1 neutralization, FC	M17/4	BE0006	BE0089
CD11a (LFA-1α)	human	Functional assays, FC	R7-1	BE0192	BE0083
CD11b	mouse/human	<i>in vivo</i> CD11b neutralization, ILC2 cell purification, FC	M1/70	BE0007	BE0090
CD16/CD32	mouse	<i>in vivo</i> and <i>in vitro</i> Fc receptor blocking	2.4G2	BE0307	BE0090
CD18	mouse	<i>in vivo</i> LFA-1 neutralization	M18/2	BE0009	BE0089
CD19	mouse	<i>in vivo</i> B cell depletion, <i>in vivo</i> CD19 neutralization, <i>in vitro</i> B cell negative selection, FC	1D3	BE0150	BE0089
CD19	human	FC, Functional assays, IF, Chimeric antigen receptor construction	4G7	BE0281	BE0083
CD20	mouse	<i>in vivo</i> B cell depletion, WB	MB20-11	BP0356	BE0366
CD20	human/monkey	<i>in vivo</i> B cell depletion in hCD20 Tg mice, IHC-F, IP, FC	2H7	BE0276	BE0086
CD20	mouse	FC, WB	AISB12	BE0302	BE0089
CD22	mouse	<i>in vivo</i> B cell depletion in combination with anti-CD19 (clone 1D3) and anti-rat K Light Chain (clone MAR 18.5), FC, IP	Cy34.1	BE0011	BE0083
CD24	mouse	<i>in vivo</i> administration, IHC-F, IHC-P, IF, FC	M1/69	BE0360	BE0090
CD25 (IL-2Rα)	mouse	<i>in vivo</i> regulatory T cell depletion, FC	PC-61.5.3	BP0012	BP0088
CD25 (IL-2Rα)	human	IP, IF	7G7B6	BE0014	BE0085
CD27	mouse	<i>in vivo</i> CD27 stimulation, <i>in vitro</i> CD27 stimulation, IP, FC	RM27-3E5	BE0348	BE0089
CD28	mouse	<i>in vivo</i> CD28 blockade, <i>in vitro</i> T cell stimulation/activation	37.51	BE0015-1	BE0087
CD28	mouse	<i>in vitro</i> T cell stimulation/activation	PV-1	BE0015-5	BE0091
CD28	rat	<i>in vitro</i> T cell stimulation/activation, FC	JJ319	BE0040	BE0083
CD28	human	<i>in vitro</i> T cell stimulation/activation	9.3	BE0248	BE0085
CD28	human/monkey	<i>in vitro</i> T cell stimulation/activation, FC, IHC-F, IP	CD28.2	BE0291	BE0083
CD28	mouse	<i>in vivo</i> and <i>in vitro</i> T cell stimulation/activation	D665	BE0328	BE0083
CD29	mouse	IF, FC	KM16	BE0232	BE0089
CD32 (FcγRIIA)	human	<i>in vivo</i> FcγRIIA blockade in humanized mice, <i>in vitro</i> FcγRIIA blockade, ELISA, FC	IV.3	BE0224	BE0086
CD38	mouse	<i>in vivo</i> and <i>in vitro</i> CD38 stimulation, <i>in vitro</i> B cell activation, IF	NIMR5	BE0317	BE0089
CD40	mouse	<i>in vivo</i> CD40 activation, <i>in vitro</i> B cell stimulation/activation	FGK4.5/FGK45	BP0016-2	BP0089
CD40	human	<i>in vitro</i> B cell stimulation, <i>in vitro</i> CD40 stimulation, <i>in vitro</i> macrophage stimulation, Functional assays, FC	G28.5	BE0189	BE0083
CD154 (CD40L)	mouse	<i>in vivo</i> and <i>in vitro</i> blocking of CD40/CD40L signaling	MR-1	BP0017-1	BP0091
CD154 (CD40L)	human/monkey	<i>in vitro</i> blocking of CD40/CD40L signaling, <i>in vivo</i> blocking of CD40/CD40L signaling, IP, FC	5C8	BE0292	BE0085



Antigen	Reactivity	Application	Clone	<i>InVivoMab</i> Catalog	<i>InVivoPlus</i> Catalog
CD44	mouse/human	<i>in vivo</i> CD44 neutralization	IM7	BE0039	BE0090
CD44	human	<i>in vivo</i> CD44 blockade in xenografts, <i>in vitro</i> CD44 blockade, WB, IF	Hermes-1	BE0262	BE0089
CD45RB	mouse	<i>in vivo</i> anti-CD45RB-mediated tolerance induction, <i>in vivo</i> pre-mNK cell depletion	MB23G2 (HB220)	BE0019	BE0089
CD45.2	mouse	<i>in vivo</i> and <i>in vitro</i> CD45.2 blockade, FC, IHC-F,	104.2	BE0300	BE0085
CD47	human	<i>in vivo</i> CD47 neutralization in human tumor xenograft models or humanized mice, <i>in vitro</i> CD47 neutralization, FC	B6H12	BE0019-1	BE0083
CD47	hu/mo/rt	<i>in vivo</i> and <i>in vitro</i> CD47 blockade, IF	MIAP410	BP0283	BP0083
CD47 (IAP)	mouse	<i>in vivo</i> CD47 blockade, <i>in vitro</i> CD47 blockade, IF	MIAP301	BE0270	BE0089
CD48	mouse	<i>in vivo</i> and <i>in vitro</i> CD48 blockade	HM48-1	BE0147	BE0091
CD49d (VLA-4)	mouse/human	<i>in vivo</i> and <i>in vitro</i> VLA-4 neutralization, FC	PS/2	BE0071	BE0090
CD54 (ICAM-1)	mouse	<i>In vivo</i> ICAM-1 neutralization	YN1/1.7.4	BE0020-1	BE0090
CD54 (ICAM-1)	human	<i>in vitro</i> T cell stimulation/activation, IF	R6-5-D6	BE0020-2	BE0085
CD62E (E-Selectin)	mouse	<i>in vivo</i> and <i>in vitro</i> E-selectin blockade, IHC-F	9A9	BE0294	BE0090
CD62L (L-Selectin)	mouse	<i>In vivo</i> CD62L neutralization	Mel-14	BE0021	BE0089
CD69	mouse	<i>in vivo</i> down-regulation of CD69 expression, Functional assays	CD69.2.2	BE0330	BE0083
CD70	mouse	<i>in vivo</i> and <i>in vitro</i> CD70 blockade, FC	FR70	BE0022	BE0090
CD71	human	FC, IHC-F	OKT9	BE0023	BE0083
CD71 (TfR)	human	WB, IP, FC	5E9C11	BE0343	BE0083
CD71 (TfR1)	mouse	<i>in vivo</i> depletion of CD71+ cells	R17 217.1.3/T1B-219	BE0175	BE0089
CD71 (TfR1)	mouse	<i>in vivo</i> depletion of CD71+ cells, IF, IHC-F, WB	8D3	BE0329	BE0089
CD71 (TfR1)	rat/mouse	Targeted drug delivery to the brain, IHC-F, FC	OX-26	BE0331	BE0085
CD73	mouse	<i>in vivo</i> CD73 blockade	TY/23	BE0209	BE0089
CD80 (B7-1)	mouse	<i>in vivo</i> B7-1 blockade, affinity chromatography	1G10	BE0134	BE0089
CD80 (B7-1)	mouse	<i>In vivo</i> CD80 blockade, FC	16-10A1	BE0024	BE0091
CD86 (B7-2)	mouse	<i>In vivo</i> CD86 blockade, FC	GL-1	BE0025	BE0089
CD90 (Thy1)	mouse	<i>in vitro</i> T cell depletion	M5/49.4.1	BE0076	BE0089
CD90.1 (Thy1.1)	mouse	<i>in vivo</i> T cell depletion	19E12	BE0214	BE0085
CD90.2 (Thy1.2)	mouse	<i>in vivo</i> ILC depletion, <i>in vivo</i> T cell depletion	30H12	BP0066	BP0090
CD91 (LRP1)	hu/mo/rt	WB, IF, IP	11H4	BE0333	BE0083
CD96	mouse	<i>in vivo</i> and <i>in vitro</i> CD96 blocking, FC	3.3	BE0337	BE0088
CD103	mouse	<i>In vivo</i> CD103 neutralization, IF, FC	M290	BE0026	BE0089
CD106 (VCAM-1)	mouse	<i>in vivo</i> VCAM-1 neutralization, IF	M/K-2.7	BE0027	BE0088
CD115 (CSF1R)	mouse	<i>in vivo</i> macrophage depletion, <i>in vivo</i> monocyte depletion, <i>in vitro</i> CSF-R1 neutralization, FC	AFS98	BP0213	BP0089
CD115 (CSF1R)	human	<i>in vitro</i> CSF1R neutralization, IHC-P, FC, Functional assays	2-4A5-4	BE0347	BE0088
CD117 (c-Kit)	mouse	FC, IF, IHC	2B8	BE0280	BE0090
CD119 (IFNγR)	mouse	<i>in vivo</i> IFNγR neutralization	GR-20	BE0029	BE0089
CD119 (IFNγRα)	mouse	WB, IP, FC	2E2	BE0287	BE0091
CD120b (TNFR2)	mouse	<i>in vivo</i> TNFR2 blockade, <i>in vitro</i> TNFR2 blockade	TR75-54.7	BE0247	BE0091
CD121a (IL-1 R)	mouse	<i>in vitro</i> IL-1 R blockade	JAMA-147	BE0256	BE0091
CD122 (IL-2Rβ)	mouse	<i>in vitro</i> NK cell negative selection, IP, FC	5H4	BE0272	BE0089
CD122 (IL-2Rβ)	mouse	<i>in vivo</i> NK cell depletion, <i>in vitro</i> IL-2R blockade, Functional assays, FC	TM-Beta 1	BE0298	BE0090
CD127 (IL-7Rα)	mouse	<i>in vivo</i> blocking of IL-7Rα signaling, FC	A7R34	BE0065	BE0089
CD132 (common γ chain)	mouse	<i>in vivo</i> γc blockade, Functional assays, IP, FC	3E12	BE0271	BE0090
CD134 (OX40)	mouse	<i>in vivo</i> and <i>in vitro</i> OX40 activation	OX-86	BP0031	BP0088
CD134L (OX40L)	mouse	<i>in vivo</i> blocking of OX40/OX40L signaling, <i>in vitro</i> OX40L neutralization	RM134L	BE0033-1	BE0090
CD137 (4-1BB)	mouse	<i>in vivo</i> activation of 4-1BB	LOB12.3	BP0169	BP0089
CD137 (4-1BB)	mouse	<i>in vivo</i> and <i>in vitro</i> 4-1BB stimulation	3H3	BP0239	BP0089
CD137 (4-1BB)	mouse	<i>in vitro</i> 4-1BB blockade, FC	17B5	BE0296	BE0087
CD137L (4-1BBL)	mouse	<i>in vivo</i> 4-1BBL blockade	TKS-1	BE0110	BE0089
CD152 (CTLA-4)	mouse	<i>in vivo</i> and <i>in vitro</i> CTLA-4 neutralization, FC	UC10-4F10-11	BP0032	BP0091
CD152 (CTLA-4)	mouse	<i>in vivo</i> and <i>in vitro</i> CTLA-4 neutralization, FC	9H10	BP0131	BP0087
CD152 (CTLA-4)	mouse	<i>in vivo</i> CTLA-4 neutralization	9D9	BP0164	BP0086



InVivoMab vs. InVivoPlus		
purity level	InVivoMab > 95%	InVivoPlus > 95%
protein aggregates validated at ≤ 5%		✓
azide and carrier protein free	✓	✓
endotoxin concentration	< 2EU/mg	< 1EU/mg
validated by immunoblot, FC, or ELISA		✓
tested for murine pathogens		✓
available in bulk quantities	✓	✓

Antigen	Reactivity	Application	Clone	InVivoMab Catalog	InVivoPlus Catalog
CD152 (CTLA-4)	human	<i>in vitro</i> CTLA-4 neutralization, FC	BN13	BE0190	BE0085
CD159 (NKG2A/C/E)	mouse	<i>in vivo</i> and <i>in vitro</i> NKG2A blockade, IHC-F, FC	20D5	BE0321	BE0089
CD161 (NK1.1)	mouse	<i>in vivo</i> NK cell depletion, FC	PK136	BP0036	BP0085
CD162 (PSGL-1)	mouse	<i>in vivo</i> PSGL-1 blockade, IHC-F	4RA10	BE0186	BE0088
CD172a (SIRPα)	mouse	<i>in vivo</i> and <i>in vitro</i> SIRPα blocking, WB, IP, FC	P84	BE0322	BE0088
CD178 (FasL)	mouse	<i>in vivo</i> and <i>in vitro</i> FasL blockade, Functional assay, IHC-P, FC	MFL3	BE0319	BE0091
CD183 (CXCR3)	mouse	<i>in vivo</i> CXCR3 neutralization, FC	CXCR3-173	BE0249	BE0091
CD193 (CCR3)	mouse	<i>in vivo</i> eosinophil depletion	6S2-19-4	BE0316	BE0090
CD200 (OX2)	mouse	<i>in vivo</i> and <i>in vitro</i> CD200 blockade, IHC-F, IF, FC	OX-90	BE0299	BE0089
CD209b (SIGN-R1)	mouse	<i>in vivo</i> SIGN-R1 blockade, IHC-F, WB, FC	22D1	BE0220	BE0091
CD210 (IL-10R)	mouse	<i>in vivo</i> blocking of IL-10/IL-10R signaling, <i>in vitro</i> blocking of IL-10R signaling, FC	1B1.3A	BP0050	BP0088
CD220 (Insulin Receptor)	human	WB	IR 83-22	BE0338	BE0083
CD223 (LAG-3)	mouse	<i>in vivo</i> and <i>in vitro</i> LAG-3 neutralization, FC	C9B7W	BP0174	BP0088
CD227 (MUC1)	human	<i>in vivo</i> administration in mouse xenograft models, <i>in vitro</i> cell cytotoxicity assay, WB, IHC-P, IF,	C595 (NCRC48)	BE0336	BE0093
CD243 (MDR-1)	human/monkey	<i>in vivo</i> MDR-1 blocking/depletion in xenogeneic murine tumor models, <i>in vitro</i> MDR-1 blocking, IHC-P	UIC2	BE0340	BE0085
CD254 (RANKL)	mouse	<i>in vivo</i> RANKL blockade	IK22/5	BE0191	BE0089
CD262 (DR5)	mouse	<i>in vivo</i> and <i>in vitro</i> induction TRAIL-mediated apoptosis	MD5-1	BE0161	BE0091
CD272 (BTLA)	mouse	<i>in vivo</i> BTLA stimulation, <i>in vivo</i> BTLA blockade	6A6	BE0132	BE0091
CD272 (BTLA)	mouse	<i>in vivo</i> and <i>in vitro</i> stimulation of BTLA, FC	PK18.6	BE0153	BE0088
CD272 (BTLA)	mouse	<i>in vivo</i> BTLA blockade, <i>in vitro</i> T cell stimulation/activation, FC	PJ196	BE0196	BE0083
CD272 (BTLA)	mouse	<i>in vivo</i> BTLA+ B cell and CD4 T cell depletion, FC	6F7	BE0304	BE0083
CD273 (PD-L2)	mouse	<i>in vivo</i> and <i>in vitro</i> PD-L2 blockade, IHC-F, FC	TY25	BE0112	BE0089
CD274 (PD-L1)	mouse	<i>in vivo</i> PD-L1 blockade, IF, IHC-F, FC	10F.9G2	BP0101	BP0090
CD275 (ICOSL)	mouse	<i>in vivo</i> ICOSL neutralization	HK5.3	BE0028	BE0089
CD276 (B7-H3)	mouse	<i>in vivo</i> B7-H3 blockade, FC	MJ18	BE0124	BE0088
CD278 (ICOS)	mouse	<i>in vivo</i> blocking of ICOS/ICOSL signaling, FC	7E.17G9	BE0059	BE0090
CD279 (PD-1)	mouse	<i>in vivo</i> blocking of PD-1/PD-L signaling, <i>in vitro</i> PD-1 neutralization	J43	BP0033-2	BP0091
CD279 (PD-1)	mouse	<i>in vivo</i> blocking of PD-1/PD-L signaling	RMP1-14	BP0146	BP0089
CD279 (PD-1)	human	<i>in vitro</i> PD-1 neutralization, <i>in vivo</i> PD-1 blockade in humanized mice	J116	BE0188	BE0083
CD279 (PD-1)	human	<i>in vivo</i> PD-1 blockade in humanized mice, FC	J110	BE0193	BE0083
CD279 (PD-1)	mouse	<i>in vivo</i> blocking of PD-1/PD-L signaling, <i>in vitro</i> PD-1 neutralization, IHC-F, FC, WB	29F.1A12	BP0273	BP0089
CD314 (NKG2D)	mouse	<i>in vivo</i> and <i>in vitro</i> NKG2D blockade, FC	CX5	BE0334	BE0088
CD317 (BST2, PDCA-1)	mouse	<i>in vivo</i> pDC depletion, IF, FC	927	BE0311	BE0090
CD324 (E-Cadherin)	mouse	<i>in vivo</i> E-Cadherin neutralization, <i>in vitro</i> E-Cadherin neutralization, IF, IP, WB	DECMA-1	BE0352	BE0088
CD326 (EpCAM)	mouse	WB, IF, IHC-F, FC	G8.8	BE0346	BE0089
CD340 HER2 (neu)	human/rat	<i>in vivo</i> and <i>in vitro</i> HER2/neu inhibition, IP, IF, FC	7.16.4	BE0277	BE0085
CD365 (TIM-1)	mouse	<i>in vivo</i> TIM-1 neutralization	RMT1-10	BE0113	BE0089
CD366 (TIM-3)	mouse	<i>in vivo</i> TIM-3 neutralization, <i>in vitro</i> TIM-3 blocking, FC	RMT3-23	BP0115	BP0089
CD366 (TIM-3)	mouse	<i>in vivo</i> TIM-3 neutralization, <i>in vitro</i> TIM-3 blocking, FC	B8.2C12	BE0275	BE0088
CD370 (CLEC9A)	mouse	<i>in vivo</i> Ag targeting to CLEC9A+ DCs, WB, ELISA, IP, IF, FC	7H11	BE0305	BP0088

IF Immunofluorescence | IHC-F Immunohistochemistry (frozen) | IHC-P Immunohistochemistry (paraffin) | WB Western blot | IP Immunoprecipitation | FC Flow cytometry (requires fluochrome conjugation)

For over 25 years, scientists have trusted Bio X Cell as their go-to source for *in vivo* functional grade antibodies. This is reflected in nearly 20,000 peer-reviewed publications citing Bio X Cell products. We understand this responsibility is of paramount importance and remain committed to producing antibodies of unparalleled quality and consistency, enabling our partners around the globe to accelerate research and discoveries.

Bio X Cell
 bioxcell.com | 1.866.787.3444
 customerservice@bioxcell.com

Conditions: For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale.

